Dec 20, 2024, 19:27 ET Alhemo® is designed to block a protein called TFPI in the body that stops blood from clotting. By blocking TFPI, Alhemo® improves the production of thrombin, a protein that helps to clot the blood and prevent bleeding, when…
ORLANDO, Fla., Dec. 7, 2015 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today presented data from its Phase III PROLONG-9FP clinical program evaluating the efficacy and long-term safety... ORLANDO, Fla., Dec. 7, 2015 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today presented data from its Phase…
Doctors say its potential to reduce bleeding episodes and the need for frequent intravenous infusions could make treatment more convenient for patients. However, affordability, access and careful safety monitoring will be crucial to its wider use. Haemophilia is an inherited…
Presented by: AJMC, Pharmacy Times & CancerNetwork Leveraging in vitro clot formulation and fibrinolysis assays may help guide personalized treatment for patients with hemophilia A, suggest findings from a new study. Detailing their findings in Research & Practice in Thrombosis & Haemostasis, the…
New Delhi: Sanofi Healthcare on Wednesday said it has received marketing authorisation from drug regulator CDSCO for Qfitlia, a therapy used to prevent bleeding in haemophilia patients. The approval from the Central Drugs Standard Control Organiation (CDSCO) covers adults and…
Sanofi Healthcare on Wednesday said it has received marketing authorisation from drug regulator CDSCO for Qfitlia, a therapy used to prevent bleeding in haemophilia patients. The approval from the Central Drugs Standard Control Organiation (CDSCO) covers adults and adolescents aged…
Fitusiran is indicated for routine prophylaxis to prevent or reduce bleeding episodes in adults and adolescents aged 12 years and older, with or without factor VIII or IX inhibitors CDSCO approves Sanofi’s Qfitlia for haemophilia A and B in India Fitusiran…
New Delhi: Pharmaceutical major Dr. Reddy's Laboratories Limited has received a positive recommendation from the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) for approval of Denosumab 120 mg/1 mL solution for injection in a pre-filled syringe…
Oct 09, 2026, 10:37 ET LUX Infusion is currently authorized to dispense Qfitlia, expanding access to a unique bleeding disorder treatment option. PLANTATION, Fla., Oct. 9, 2026 /PRNewswire/ -- LUX Infusion (the "Company"), a clinician-led infusion service network, today announced the availability of Qfitlia (fitusiran), which…
The state-of-the-art treatment will be provided entirely free of cost, reducing the medical burden on patients and their families while improving their quality of life. Saha made the announcement while inaugurating the service at a programme held at the auditorium…
Haemophilia and other bleeding disorders: gene therapy, new treatments and life with a bleeding disorder.
An article joins this feed when it matches these terms. Each one is also a search of its own.